Comparing two treatments for low-risk elderly breast cancer patients after surgery
Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
This study is testing whether a type of radiation treatment after surgery can help older women with low-risk breast cancer feel better compared to taking hormone therapy alone.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 65 Years and up |
| Sex | Female |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Trial ID | NCT05472792 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the quality of life and oncologic outcomes in low-risk elderly women with breast cancer who have undergone lumpectomy. Participants aged 65 and older will be randomized to receive either accelerated partial breast irradiation (APBI) or endocrine therapy alone. APBI involves delivering radiation therapy in five fractions to the lumpectomy cavity, while endocrine therapy will be selected by the treating oncologist for a duration of five years. The study aims to determine if APBI provides better quality of life compared to endocrine therapy while maintaining similar disease control and survival rates.
Who should consider this trial
Good fit: Ideal candidates are women aged 65 and older with low-risk, hormone receptor-positive breast cancer who have undergone lumpectomy.
Not a fit: Patients with high-risk tumor characteristics or those who have not undergone lumpectomy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into more effective treatment options that enhance the quality of life for elderly breast cancer patients.
How similar studies have performed: Other studies have shown promising results with similar approaches, but this specific comparison of APBI and endocrine therapy in this demographic is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing and able to provide written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. 2. Women greater than or equal to age 65 years with de novo invasive carcinoma of breast. 3. Pathological T1 (pT1) stage 4. Estrogen receptor (ER)/ Progesterone receptor (PR) positive (greater than or equal to 10% ER and PR by immunohistochemistry \[IHC\] staining) 5. Human epidermal growth factor receptor 2 (HER2) - according to American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guidelines (0 or 1+ following IHC staining or proven negative by in-situ hybridization \[ISH\]) 6. Grade 1 or 2 overall tumor grade 7. Clinical or pathological N0 8. No lymphovascular space invasion (LVSI) 9. Final surgical margins ≥ 2 mm as per APBI criteria 10. Subjects with completed breast conserving surgery (BCS) with or without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). 11. Suitable for APBI as deemed by the treating radiation oncologist 12. Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. 13. Enrollment in another clinical trial is allowed if there would be no interference with interventions on this trial Exclusion Criteria: 1. Pre- or post-operative systemic chemotherapy while on this study. 2. Current ongoing treatment with anti-hormonal agents. If previously on anti-hormonal agents and planning to stop, the subject must discontinue within 30 days of randomization. 3. Hormonal replacement therapy (eligible if discontinued within 30 days of randomization). 4. Multifocal or multicentric tumor. 5. Receipt of tissue rearrangement in the lumpectomy cavity. 6. Synchronous bilateral breast cancer. 7. Clinical or imaging evidence of distant metastases. 8. Prior breast or thoracic radiation. 9. Autoimmune conditions with associated radiation risks. 10. Subjects with poor medical risk due to uncontrolled medical conditions that would deem them ineligible for hormonal or radiation therapy.
Where this trial is running
Chapel Hill, North Carolina
- University of North Carolina — Chapel Hill, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Dana Casey, MD — University of North Carolina, Chapel Hill
- Study coordinator: Lori Stravers
- Email: lori_stravers@med.unc.edu
- Phone: +1 919-966-4432
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.